- Signed a definitive agreement to acquire dermatology and oral solids businesses from Sandoz Inc., USA.
- Signed a definitive agreement to acquire Apotex Inc’s commercial operations in 5 European countries.
- Started filing Oncology & Hormones, Dermatology and Nasal ANDAs in US.
- Acquired Generis in Portugal - Focus on differentiated technology platforms and Specialty Pharmaceuticals.
- Acquired four cell-culture derived biosimilar products from TL Biopharmaceutical AG.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. I AcceptCookie policy